Table 4 Adverse events of special interest – infections
Preferred Term | NNS/CANDLE (N = 5) n (%) | SAVI (N = 3) n (%) | AGS (N = 1) n (%) | Total (N = 9) n (%) |
|---|---|---|---|---|
Patients ≥ 1 TEAE | 3 (60.0) | 2 (66.7) | 1 (100.0) | 6 (66.7) |
Upper respiratory tract infection | 1 (20.0) | 1 (33.3) | 0 (0.0) | 2 (22.2) |
Atypical mycobacterial infection | 0 | 1 (33.3) | 0 (0.0) | 1 (11.1) |
BK virus infection | 1 (20.0) | 0 | 0 (0.0) | 1 (11.1) |
Bronchopulmonary aspergillosis | 0 (0.0) | 1 (33.3) | 0 (0.0) | 1 (11.1) |
Conjunctivitis | 0 (0.0) | 1 (33.3) | 0 (0.0) | 1 (11.1) |
Cytomegalovirus chorioretinitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
Folliculitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
Localized infection | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
Periodontitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
Pharyngitis | 0 (0.0) | 0 (0.0) | 1 (100.0) | 1 (11.1) |
Pneumocystis jirovecii pneumonia | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
Pneumonia cytomegaloviral | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |
Tinea capitis | 1 (20.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) |